FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2028674500> ?p ?o ?g. }

• W2028674500 endingPage "421" @default.
• W2028674500 startingPage "411" @default.
• W2028674500 abstract "This trial was designed to determine the maximum tolerated dose of intravenous daunorubicin (DNR) in combination with valspodar and to test the feasibility of P-glycoprotein modulation using valspodar in elderly patients with previously untreated acute myelogenous leukemia receiving standard induction chemotherapy.Patients > or =60 years of age with previously untreated AML received valspodar (10 mg/kg/24 h by continuous intravenous infusion [CIV] on days 1-4 with a 2-mg/kg loading dose on day 1) in conjunction with two cycles of induction chemotherapy consisting of cytarabine (200 mg/m(2) CIV on days 1-7), and DNR (35 mg/m(2) [cohort 1] or 45 mg/m(2) [cohort 2] on days 1-3, intravenous bolus). Patients were assessed for dose-limiting toxicities (DLT), response rate, event-free and overall survival, and pharmacokinetics of valspodar and DNR.Valspodar was well tolerated at the lower DNR dose level (ie, 35 mg/m(2)) resulting in a 21% rate of DLT and only three toxic deaths. Treatment-related mortality was unacceptably high at the 45 mg/m(2) DNR dose level. The complete response rate was 49% overall and similar in both cohorts. The median overall survival of patients was 333 days in cohort 1 compared to 98 days in cohort 2. At baseline, 70% of assessable patients were P-glycoprotein positive.Substantial inhibition of P-glycoprotein activity can be achieved in this patient population at clinically tolerable doses of valspodar and DNR. The maximum tolerated dose of DNR was established as 35 mg/m(2). This regimen is being further evaluated in phase III trials." @default.
• W2028674500 created "2016-06-24" @default.
• W2028674500 creator A5002972322 @default.
• W2028674500 creator A5011578211 @default.
• W2028674500 creator A5013411479 @default.
• W2028674500 creator A5013645809 @default.
• W2028674500 creator A5015933270 @default.
• W2028674500 creator A5018592613 @default.
• W2028674500 creator A5022108188 @default.
• W2028674500 creator A5024141611 @default.
• W2028674500 creator A5030424335 @default.
• W2028674500 creator A5033391337 @default.
• W2028674500 creator A5046775582 @default.
• W2028674500 creator A5047984145 @default.
• W2028674500 creator A5050532707 @default.
• W2028674500 creator A5051639897 @default.
• W2028674500 creator A5070124187 @default.
• W2028674500 creator A5072582820 @default.
• W2028674500 date "2000-01-01" @default.
• W2028674500 modified "2023-10-15" @default.
• W2028674500 title "Dose-finding study of valspodar (PSC 833) with daunorubicin and cytarabine to reverse multidrug resistance in elderly patients with previously untreated acute myeloid leukemia" @default.
• W2028674500 cites W1492445977 @default.
• W2028674500 cites W1591450638 @default.
• W2028674500 cites W1723032639 @default.
• W2028674500 cites W1757201400 @default.
• W2028674500 cites W1925223276 @default.
• W2028674500 cites W1981267478 @default.
• W2028674500 cites W1990023576 @default.
• W2028674500 cites W1990189905 @default.
• W2028674500 cites W1990431470 @default.
• W2028674500 cites W2003484346 @default.
• W2028674500 cites W2006413929 @default.
• W2028674500 cites W2010336145 @default.
• W2028674500 cites W2011564019 @default.
• W2028674500 cites W2016756053 @default.
• W2028674500 cites W2024463580 @default.
• W2028674500 cites W2026392633 @default.
• W2028674500 cites W2028533496 @default.
• W2028674500 cites W2028917256 @default.
• W2028674500 cites W2031186545 @default.
• W2028674500 cites W2033354680 @default.
• W2028674500 cites W2036571761 @default.
• W2028674500 cites W2038917418 @default.
• W2028674500 cites W2043201907 @default.
• W2028674500 cites W2049683781 @default.
• W2028674500 cites W2067462298 @default.
• W2028674500 cites W2086663675 @default.
• W2028674500 cites W2105643967 @default.
• W2028674500 cites W2118234018 @default.
• W2028674500 cites W2121476898 @default.
• W2028674500 cites W2127813576 @default.
• W2028674500 cites W2138993111 @default.
• W2028674500 cites W2159050931 @default.
• W2028674500 cites W2165294243 @default.
• W2028674500 cites W2167564928 @default.
• W2028674500 cites W2228456847 @default.
• W2028674500 cites W2279474976 @default.
• W2028674500 cites W2318674152 @default.
• W2028674500 cites W2327443350 @default.
• W2028674500 cites W2335886634 @default.
• W2028674500 cites W2339692928 @default.
• W2028674500 cites W2340895045 @default.
• W2028674500 cites W2399174605 @default.
• W2028674500 cites W2409889656 @default.
• W2028674500 cites W2410434383 @default.
• W2028674500 cites W2416658814 @default.
• W2028674500 cites W2418441271 @default.
• W2028674500 cites W2441999485 @default.
• W2028674500 cites W2464283931 @default.
• W2028674500 cites W2467345388 @default.
• W2028674500 cites W2764775166 @default.
• W2028674500 cites W3146129082 @default.
• W2028674500 cites W329750643 @default.
• W2028674500 cites W55001683 @default.
• W2028674500 cites W61975600 @default.
• W2028674500 doi "https://doi.org/10.1038/sj.thj.6200050" @default.
• W2028674500 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11920222" @default.
• W2028674500 hasPublicationYear "2000" @default.
• W2028674500 type Work @default.
• W2028674500 sameAs 2028674500 @default.
• W2028674500 citedByCount "25" @default.
• W2028674500 countsByYear W20286745002013 @default.
• W2028674500 countsByYear W20286745002015 @default.
• W2028674500 countsByYear W20286745002019 @default.
• W2028674500 crossrefType "journal-article" @default.
• W2028674500 hasAuthorship W2028674500A5002972322 @default.
• W2028674500 hasAuthorship W2028674500A5011578211 @default.
• W2028674500 hasAuthorship W2028674500A5013411479 @default.
• W2028674500 hasAuthorship W2028674500A5013645809 @default.
• W2028674500 hasAuthorship W2028674500A5015933270 @default.
• W2028674500 hasAuthorship W2028674500A5018592613 @default.
• W2028674500 hasAuthorship W2028674500A5022108188 @default.
• W2028674500 hasAuthorship W2028674500A5024141611 @default.
• W2028674500 hasAuthorship W2028674500A5030424335 @default.
• W2028674500 hasAuthorship W2028674500A5033391337 @default.
• W2028674500 hasAuthorship W2028674500A5046775582 @default.
• W2028674500 hasAuthorship W2028674500A5047984145 @default.
• W2028674500 hasAuthorship W2028674500A5050532707 @default.

• next